Introduction {#s1}
============

Gastric cancer (GC) is the fifth most common cancers and the third leading cause of cancer death worldwide ([@B1]). Almost one million new cases of GC were diagnosed each year, and about 50% of them occurred in Eastern Asia (mainly in China) ([@B2]). Although an improvement of 5-years survival for GC was observed in the past 10 years, the prognosis of Chinese GC patients was still poor. Compared with a very high survival of GC in Korea (68·9%) and Japan (60·3%), the age-standardized 5-years relative survival was only 35.1% in China because most patients have inoperable disease at the time of initial presentation ([@B3]--[@B5]).

Gastrectomy is the only potentially curative therapy for resectable GC, but a major proportion of patients could have local or distant recurrence even after curative resection ([@B6], [@B7]). People with metastatic GC have a poor prognosis with a median survival time of around 4 months in the absence of systemic chemotherapy ([@B5]). For patients with metastatic diseases, it has been demonstrated in multiple trials and meta-analysis that systemic chemotherapy could extend overall survival (OS) by about 7 months more than best supportive care ([@B8]). Therefore, systemic chemotherapy is the standard treatment modality for stage IV GC patients. However, systemic chemotherapy still cannot provide significant survival benefits and the disease will progress ultimately. Although some clinical guidelines had recommendations about second- and further-line treatment regimen currently, there is still no global consensus across countries regarding the best therapeutic approach after failure of the first-line therapy ([@B9], [@B10]). The management of patients with metastatic GC is challenging.

Recent years, the number of options available for GC has been increasing rapidly ([@B11]). In addition to the development of new anticancer drugs, multi-modality treatments, such as palliative surgery, radiation therapy, intraperitoneal chemotherapy, and other approaches, are gaining support in the management of metastatic gastric cancer ([@B12]--[@B18]). However, despite these advances, their impact on long-term survival outcome for patients with metastatic GC remains unsatisfactory and the best form of multidisciplinary therapeutic strategy is still not established. In this real-world study, we will focus on the role of multi-modality treatment for patients with metastatic GC.

Methods {#s2}
=======

Study Design and Participants
-----------------------------

Between December 2011 and November 2018, a total of 267 patients with initial stage IV gastric cancer in Peking Union Medical College Hospital were included consecutively. The eligibility criteria were: (1) histologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma; (2) distant metastases verified by enhanced computed tomography (CT) or other approaches; (3) over 18 years old; (4) ECOG 0-2; (5) received first-line systematic treatment. Patients were divided into two groups according to treatment modality: the multi-modality treatment group comprised 114 patients and the chemotherapy only group comprised 153 patients. The multi-modality treatment group was defined as patients who received both systematic chemotherapy and other modality treatments including palliative gastrectomy and metastasectomy, intraperitoneal chemotherapy, radiotherapy, radiofrequency ablation, and transarterial chemoembolization (TACE). The chemotherapy only group was defined as patients who received systematic chemotherapy alone. This study was approved by the ethics committee of Peking Union Medical College Hospital.

Treatment
---------

The treatment regimens of gastric cancer were mainly based on clinical guidelines of the Chinese Society of Clinical Oncology (CSCO) and the National Comprehensive Cancer Network (NCCN) ([@B12], [@B19]). Several cytotoxic agents are adopted to treat metastatic gastric cancer, including fluoropyrimidines (5-fluorouracil, S-1, capecitabine), platinum agents (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and irinotecan. For some patients with human epidermal growth factor receptor 2 (HER2)-overexpressing tumors, trastuzumab is combined with cytotoxic chemotherapy. The method used by the hospital to test the HER2 status was immunohistochemistry and fluorescence *in situ* hybridization (FISH). Each patient\'s chemotherapy plan (including intraperitoneal perfusion) is individualized by senior medical oncologists in the department of medical oncology depending on the tolerance and response to different treatment regimens. All patients in this study received first-line chemotherapy. If patients had disease progression evaluated by medical oncologists and good performance status, they would consider receiving second- or further-line treatment. The palliative gastrectomy or metastasectomy were performed by surgeons from different specialties. Appropriate radiotherapy plan was determined by radiation oncologists based on the patient\'s general condition, irradiation field, possible normal tissue damage and so on. Radiofrequency ablation and TACE were performed by specialists from the department of radiology.

Assessment and Follow-Up
------------------------

The following assessment were applied every two to three cycles typically: detailed medical history, physical examination, serum tumor marker analysis, and contrast enhanced CT of the chest, abdomen and pelvis. Additional approaches such as positron emission tomography (PET) and bone scan were undertaken depending on a clinical suspicion of recurrence or metastasis. Radiographic tumor response is quantified by using Response Evaluation Criteria in Solid Tumors (RECIST).

All patients followed up every 3 months, either in a clinical visit or by telephone. At each the out-patient review, physical examination, necessary radiological examinations (enhanced CT or occasional PET-CT), and routine laboratory examinations were performed regularly. The follow-up data were updated until January 31, 2019.

Statistical Analysis
--------------------

All statistical analyses were performed using SPSS software (version 25, IBM Corp., Armonk, NY, USA). The OS is defined as the interval from the stage IV disease diagnosis to the latest follow-up or death. Continuous variables were assessed by *t*-test, and categorical variables were analyzed with Chi squared test. Related survival curves were constructed according to the Kaplan-Meier method, and a log-rank test was applied to compare these curves. The Cox proportional hazards regression model was adopted to identify the independent prognostic factors for survival, variables (*P* \< 0.10) in univariate analysis were entered into multivariate analysis. A *P* \< 0.05 was considered significant.

Results {#s3}
=======

Patient Characteristics
-----------------------

The baseline characteristics of patients at diagnosis of metastatic disease are shown in [Table 1](#T1){ref-type="table"}. The average age of included patients was 56.4 years old, and 67.8% of the participants were male. At the time of stage IV disease diagnosis, the metastatic sites included peritoneum (31.8%), liver (28.1%), Krukenberg tumor (14.2%), lung (6.0%), bone (9.4%), non-regional lymph nodes (43.8%), and other distant metastases (22.8%). The multimodality treatment group displayed a higher proportion of Krukenberg tumors (19.3% vs. 10.5%, *P* = 0.041) than the chemotherapy only group. Curative surgery was performed in 37.1% of patients before the diagnosis of metastatic disease. Neoadjuvant treatment and adjuvant treatment were given to 23.2 and 85.9% of patients who underwent curative resection separately. The median follow-up periods of multimodality treatment group and chemotherapy only group were 60.4 (95%CI: 50.4--76.5) months and 63.5 (95%CI: 44.7--82.3) months, respectively. There was no statistical difference between the multimodality treatment group and the chemotherapy only group in age, sex, histologic differentiation, HER2 status, tumor location, tumor marker level at diagnosis, number of metastatic sites, previous curative resection, and follow-up period.

###### 

Baseline characteristics of patients with metastatic gastric cancer.

  **Characteristic, *n* (%)**                 **Total (*n* = 267)**   **Multimodality treatment (*n* = 114)**   **Chemotherapy only (*n* = 153)**   ***P*-value**
  ------------------------------------------- ----------------------- ----------------------------------------- ----------------------------------- ---------------
  Age (years), mean ± SD                      56.4 ± 12.5             55.3 ± 11.9                               57.1 ± 12.8                         0.242
  Sex                                         0.257                                                                                                 
    Male                                      181 (67.8)              73 (64.0)                                 108 (70.6)                          
    Female                                    86 (32.2)               41 (36.0)                                 45 (29.4)                           
  Differentiation                             0.565                                                                                                 
    Well/median                               61 (22.8)               28 (24.6)                                 33 (21.6)                           
    Poor                                      206 (77.2)              86 (75.4)                                 120 (78.4)                          
  HER2 status                                 0.520                                                                                                 
    Positive                                  54 (20.2)               26 (22.8)                                 28 (18.3)                           
    Negative                                  98 (36.7)               43 (37.7)                                 55 (35.9)                           
    Unknown                                   115 (43.1)              45 (39.5)                                 70 (45.8)                           
  Tumor location                              0.496                                                                                                 
    Upper                                     79 (29.6)               29 (25.4)                                 50 (32.7)                           
    Middle                                    86 (32.2)               36 (31.6)                                 50 (32.7)                           
    Lower                                     94 (35.2)               45 (39.5)                                 49 (32.0)                           
    Diffuse                                   8 (3.0)                 4 (3.5)                                   4 (2.6)                             
  CA19--9 level                               0.184                                                                                                 
    Normal                                    161 (60.3)              74 (64.9)                                 87 (56.9)                           
    Elevated                                  106 (39.7)              40 (35.1)                                 66 (43.1)                           
  CEA level                                   0.062                                                                                                 
    Normal                                    144 (53.9)              69 (60.5)                                 75 (49.0)                           
    Elevated                                  123 (46.1)              45 (39.5)                                 78 (51.0)                           
  Metastatic site                                                                                                                                   
    Peritoneum                                85 (31.8)               43 (37.7)                                 42 (27.5)                           0.075
    Liver                                     75 (28.1)               27 (23.7)                                 48 (31.4)                           0.167
    Krukenberg                                38 (14.2)               22 (19.3)                                 16 (10.5)                           0.041
    Lung                                      16 (6.0)                7 (6.1)                                   9 (5.9)                             0.930
    Bone                                      25 (9.4)                7 (6.1)                                   18 (11.8)                           0.119
    Non-regional lymph nodes                  117 (43.8)              45 (39.5)                                 72 (47.1)                           0.217
    Other                                     61 (22.8)               25 (21.9)                                 36 (23.5)                           0.925
  Number of metastatic sites                  0.529                                                                                                 
    1                                         138 (51.7)              63 (55.3)                                 75 (49.0)                           
    2                                         80 (30.0)               33 (28.9)                                 47 (30.7)                           
    ≥3                                        49 (18.3)               18 (15.8)                                 31 (20.3)                           
  Curative surgery                            99 (37.1)               46 (40.4)                                 53 (34.6)                           0.339
    Neoadjuvant treatment                     23 (23.2)               10 (21.7)                                 13 (24.5)                           0.257
    Adjuvant treatment                        85 (85.9)               39 (84.8)                                 46 (86.8)                           0.225
  Follow-up period (months), median (95%CI)   63.5 (50.4--76.5)       60.4 (48.3--72.5)                         63.5 (44.7--82.3)                   0.492

Treatment
---------

In the first-line systematic treatment, 4.1% of them received a single drug treatment (fluoropyrimidine, taxane, or irinotecan monotherapy), 78.3% of them received a two-drug combination (fluoropyrimidine, platinum, or taxane), and 7.5% of them received a three-drug combination ([Table 2](#T2){ref-type="table"}). Only 4.9% patients received trastuzumab targeted therapy. Second-line therapy was administered in about half of patients. Among the patients that received second-line chemotherapy, the most frequent regimen type was still two-drug combination ([Table 2](#T2){ref-type="table"}). Irinotecan or apatinib were prescribed in single agent or double agent combination regimen in second- or further-line treatment. The multimodality treatment group had a higher proportion of receiving third- (33.3 vs. 20.3%, *P* = 0.016) and further-line (13.2 vs. 5.9%, *P* = 0.040) systematic treatment than chemotherapy alone group. There was no statistical difference between these two groups in the chemotherapy regimen.

###### 

Treatment regimens of patients with metastatic gastric cancer.

  **Characteristic, *n* (%)**                                                      **Total (*n* = 267)**   **Multimodality treatment (*n* = 114)**   **Chemotherapy only (*n* = 153)**   ***P*-value**
  -------------------------------------------------------------------------------- ----------------------- ----------------------------------------- ----------------------------------- ---------------
  First-line treatment                                                             267 (100)               114 (100)                                 153 (100)                           1.000
    Single-agent (fluoropyrimidine or taxane)                                      11 (4.1)                3 (2.6)                                   8 (5.2)                             
    Double agent combination (fluoropyrimidine, platinum, or taxane)               209 (78.3)              89 (78.1)                                 120 (78.4)                          
    Taxane + platinum + Fluoropyrimidine                                           20 (7.5)                10 (8.8)                                  10 (6.5)                            0.654
    Trastuzumab involved                                                           13 (4.9)                7 (6.1)                                   6 (3.9)                             
    Others                                                                         14 (5.2)                5 (4.4)                                   9 (5.9)                             
  Second-line treatment                                                            139 (52.1)              67 (58.8)                                 72 (47.1)                           0.058
    Single agent (fluoropyrimidine, taxane, or irinotecan)                         14 (10.1)               5 (7.5)                                   9 (12.5)                            
    Double agent combination (fluoropyrimidine, platinum, taxane, or irinotecan)   102 (73.4)              49 (73.1)                                 53 (73.6)                           
    Apatinib                                                                       12 (8.6)                7 (10.4)                                  5 (6.9)                             0.683
    Trastuzumab involved                                                           8 (5.8)                 5 (7.5)                                   3 (4.2)                             
    Others                                                                         3 (2.2)                 1 (1.5)                                   2 (2.8)                             
  Third-line treatment                                                             69 (25.8)               38 (33.3)                                 31 (20.3)                           0.016
    Single agent (fluoropyrimidine, taxane, or irinotecan)                         13 (18.8)               5 (13.2)                                  8 (25.8)                            
    Double agent combination (fluoropyrimidine, platinum, taxane or irinotecan)    35 (50.7)               22 (57.9)                                 13 (41.9)                           
    Apatinib                                                                       13 (18.8)               5 (13.2)                                  8 (25.8)                            0.255
    Trastuzumab involved                                                           7 (10.1)                5 (13.2)                                  2 (6.5)                             
    Others                                                                         1 (1.4)                 1 (2.6)                                   0 (0)                               
  Further-line treatment                                                           24 (9.0)                15 (13.2)                                 9 (5.9)                             0.040

Among 114 patients who received multimodality treatment, 35 (30.7%) received palliative gastrectomy and 19 (16.7%) received metastasectomy ([Table 3](#T3){ref-type="table"}). The metastasectomy includes oophorectomy, adrenalectomy, hepatectomy, colectomy, and retroperitoneal lymphadenectomy. Fifty-two patients (45.6%) received palliative radiotherapy. In 37 patients who had peritoneal carcinomatosis and received intraperitoneal chemotherapy, fluoropyrimidine, or platinum agents were used most frequently. In addition, six patients with liver metastasis received TACE and six patients with liver metastasis received radiofrequency ablation.

###### 

Treatment regimens of patients received multimodality treatment.

  **Treatment regimens, *n* (%)**   **Multimodality treatment (*n* = 114)**
  --------------------------------- -----------------------------------------
  Palliative gastrectomy            35 (30.7)
  Metastasectomy                    19 (16.7)
  Oophorectomy                      15 (78.9)
  Adrenalectomy                     1 (5.3)
  Hepatectomy                       1 (5.3)
  Colectomy                         1 (5.3)
  Retroperitoneal lymphadenectomy   1 (5.3)
  Intraperitoneal chemotherapy      37 (32.5)
  Platinum                          18 (48.6)
  Fluoropyrimidine                  15 (40.5)
  Taxane                            4 (10.8)
  Radiotherapy                      52 (45.6)
  Radiofrequency ablation           6 (5.3)
  TACE                              6 (5.3)
  Others                            2 (1.8)

Survival
--------

The median OS of patients who received multimodality treatment was prolonged significantly than patients who received systematic treatment only (18.4 vs. 11.4 months, *P* \< 0.001, [Figure 1](#F1){ref-type="fig"}).

![Kaplan--Meier curve of overall survival in multimodality treatment group and chemotherapy only group.](fonc-09-01155-g0001){#F1}

Univariate analysis of clinical prognostic factors that might influence the survival was performed on all included patients. The results demonstrated that factors such as differentiation, CA19--9 level, previous curative surgery, palliative gastrectomy, metastasectomy, and radiotherapy were correlated with OS ([Table 4](#T4){ref-type="table"}). Multivariate analysis was performed by incorporating related factors with Cox regression, and the results indicated that differentiation, CA19--9 level, previous curative surgery, palliative gastrectomy, and metastasectomy were the independent prognostic factors of OS. In the multimodality treatment group, patients who received palliative surgery (gastrectomy or metastasectomy) also had a longer survival than those who received intraperitoneal chemotherapy or radiotherapy (21.6 vs. 15.2 months, *P* = 0.014, [Figure 2](#F2){ref-type="fig"}).

###### 

Prognostic factors for OS of patients with metastatic gastric cancer on the univariate and multivariate analysis.

  **Characteristic**                      ***n***   **MST (m)**   **Univariate analysis**   **Multivariate analysis**                          
  --------------------------------------- --------- ------------- ------------------------- --------------------------- ---------------------- ---------
  Age                                     267       14.0          1.003 (0.993--1.014)      0.567                                              
  Gender                                                                                    0.865                                              
   Male                                   181       13.4          Ref                                                                          
   Female                                 86        15.2          1.024 (0.779--1.346)                                                         
  Location                                                                                  0.305                                              
   Upper                                  79        14.1          Ref                                                                          
   Middle                                 86        13.1          1.260 (0.905--1.755)      0.171                                              
   Lower                                  94        15.4          0.974 (0.702--1.353)      0.877                                              
   Diffuse                                8         14.2          1.423 (0.681--2.973)      0.348                                              
  Differentiation                                                                           0.022                                              0.001
   Well/median                            61        21.3          Ref                                                   Ref                    
   Poor                                   206       13.1          1.443 (1.053--1.977)                                  1.723 (1.231--2.410)   
  CA19--9 level                                                                             \<0.001                                            0.011
   Normal                                 161       15.6          Ref                                                   Ref                    
   Elevated                               106       12.2          1.604 (1.219--2.110)                                  1.459 (1.089--1.956)   
  CEA level                                                                                 0.056                                              0.134
   Normal                                 144       15.4          Ref                                                   Ref                    
   Elevated                               123       12.2          1.291 (0.993--1.678)                                  1.246 (0.935--1.660)   
  Curative surgery                                                                          \<0.001                                            \<0.001
   No                                     169       12.2          Ref                                                   Ref                    
   Yes                                    98        18.3          0.605 (0.461--0.795)                                  0.588 (0.440--0.786)   
  Second- and further-line chemotherapy                                                     0.859                                              
   No                                     128       11.3          Ref                                                                          
   Yes                                    139       15.2          0.976 (0.751--1.270)                                                         
  Palliative gastrectomy                                                                    0.044                                              0.014
   No                                     232       13.2          Ref                                                   Ref                    
   Yes                                    35        18.4          0.661 (0.442--0.989)                                  0.590 (0.387--0.899)   
  Metastasectomy                                                                            0.001                                              0.007
   No                                     248       13.2          Ref                                                   Ref                    
   Yes                                    19        35.6          0.423 (0.249--0.720)                                  0.468 (0.270--0.810)   
  Intraperitoneal chemotherapy                                                              0.474                                              
   No                                     230       13.2          Ref                                                                          
   Yes                                    37        17.6          0.872 (0.604--1.264)                                                         
  Radiotherapy                                                                              0.024                                              0.325
   No                                     215       13.2          Ref                                                   Ref                    
   Yes                                    52        17.6          0.682 (0.489--0.952)                                  0.842 (0.597--1.186)   

![Kaplan--Meier curve of overall survival of patients who received palliative surgery (gastrectomy or metastatectomy) and other treatments (intraperitoneal chemotherapy or radiotherapy) in multimodality treatment group.](fonc-09-01155-g0002){#F2}

Discussion {#s4}
==========

This real-world single center study showed that median survival of patients with stage IV gastric cancer who received multimodality treatment was significantly longer compared with those who received systematic therapy alone. In multivariate analysis, palliative gastrectomy, and metastasectomy were identified as independent improved survival factors, while second- and further-line chemotherapy, radiotherapy, and intraperitoneal chemotherapy were considered to be irrelevant.

Patients with stage IV GC usually have a poor prognosis and several randomized studies have provided evidence that first-line chemotherapy is more effective in terms of survival than best supportive care alone for patients with metastatic tumors ([@B8]). Therefore, patients with metastatic GC are primarily considered for systemic chemotherapy. However, treatment options after failure of standard first-line therapy are scarce and related benefit has to be weighed against treatment-related toxicities. Some randomized trials showed a survival advantage of the second- and further-line treatment over the best supportive care ([@B20]--[@B23]). However, such benefit was not seen in this real-world study even most patients still received two-drug combination regimen in the second- and further-line chemotherapy.

Surgery is not a standard treatment option for patients with stage IV GC, except for those who need alleviate symptoms such as bleeding and obstruction caused by the tumor ([@B24]). Although patients with metastases from gastric cancer are traditionally treated with systematic chemotherapy, this research and several retrospective studies indicated that gastrectomy or metastasectomy offered a more favorable survival compared with palliative chemotherapy alone by removing macroscopic lesions remaining ([@B25]--[@B29]). Even in the multimodality treatment group, patients who received surgery had a better survival than those who only received intraperitoneal chemotherapy or radiotherapy in our study. However, the clinical benefit of palliative surgery for stage IV GC is uncertain. A significant problem of these reports is selection bias. Candidates for surgical resection were more likely to have smaller disease burden and better performance status than those who received no surgical intervention. Recently, a phase III, randomized controlled trial (REGATTA trial) failed to show any survival benefit of gastrectomy in patients with advanced gastric cancer ([@B30]). Furthermore, patients undergoing gastrectomy had a significantly higher incidence of several serious adverse events related to chemotherapy in REGATTA trial. However, because of the presence of micrometastatic disease in advanced GC, it is more reasonable for advanced GC patients to receive the palliative surgery following a good response to systemic therapy. Palliative surgery in metastatic GC is a highly controversial topic, and the door to surgical resection are still not definitely closed ([@B31]). In the future, the effect of palliative resection in stage IV GC should be assessed as a component of multimodal treatment.

Peritoneal metastases are detected in about 30% of patients with advanced gastric cancer ([@B32]). Intraperitoneal chemotherapy is a reasonable strategy to approach peritoneal metastasis directly since it enables relatively high concentration of anticancer drugs to directly target cancer lesions in the peritoneum ([@B33]--[@B35]). In addition, patients with peritoneal metastasis can benefit from intraoperative chemotherapy administration combined with surgery ([@B36]). However, intraperitoneal chemotherapy in the current study yielded conflicting results and did not demonstrate a survival benefit. Similarly, the PHOENIX-GC trial failed to show statistical superiority of intraperitoneal paclitaxel in terms of overall survival ([@B37]). The possible clinical benefits of intraperitoneal chemotherapy for GC still need exploratory clinical trials.

In this research, palliative radiation therapy as a single modality in multivariate analysis also did not improve survival of metastatic GC patients. However, it is still attractive and has a well-defined role in symptomatic palliation in patients with unresectable gastric cancer, such as pain, bleeding, and obstruction ([@B38]). A population-based study demonstrated that radiation, surgery, or combination of both were associated with improved survival in advanced GC patients ([@B39]). The role of radiation therapy in stage IV GC remains controversial.

Our study has some limitations. First, this study was a retrospective design. Because of the retrospective nature, the selection bias exists inevitably and may influence the survival analysis. For example, patients with better status and less comorbidities are more likely to undergo more aggressive treatments, which may result in a better survival outcome. Second, this research was performed at a single institute. The indication for multi-modality therapy is various and dependents on the institute, the patients included in our center cannot represent the whole population of patients with stage IV GC who received multi-modality treatments. Third, as a real-world study, the heterogenous treatment schemes may be potential confounding variables that may influence the survival result although we have used the Cox regression analysis.

Up to now, it is impractical to cure stage IV GC, but the evidence is clear that using only one treatment modality cannot control this metastatic disease efficiently. Medical oncologists, surgeons, and radiologists from different disciplines should work together and offer the patients a comprehensive treatment plan to offer a chance of survival improvement. Optimal management of patients with metastatic GC is still challenging usually requires the integration of multidisciplinary therapeutic strategies either concurrently or sequentially.

Conclusion {#s5}
==========

In conclusion, this real-world study provided the evidence that multi-modality treatment showed a significant survival benefit for patients with metastatic gastric cancer. Palliative gastrectomy and metastasectomy were independent prognostic factors for survival. In the future, large-scale prospective randomized clinical trials are needed to determine the optimal treatment strategy for stage IV gastric cancer.
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